AvertD https://validator.w3.org/feed/docs/rss2.html Prescient Medicine and Erasmus MC Partner to Study Opioid Addiction Risk SOLVD Health Launches 5-Year Post-Approval Study for AvertD® Genetic Test FDA Approves First Test to Identify Elevated Risk of Developing OUD FDA Gives PMA Supplement Approval for Use of INFINITI HTS with AvertD® SOLVD Health Receives New York State Laboratory Approval Management Solutions for Opioid Epidemic Are Similar to Management of the COVID-19 Pandemic What is Pharmacogenomics (PGx) Testing? Prescient Medicine Holdings is Now SOLVD Health